CXCL9 is influenced by immunosuppression therapy. (A) ELISA results from the UM cohort of median plasma concentrations of CXCL9 from cGVHD patients on no immunosuppressive therapy at the time of sample acquisition (n = 19), cGVHD on any immunosuppressive therapy at the time of sample acquisition (n = 43), and patients with no cGVHD (n = 82). (B) ELISA results from the FHCRC of median plasma concentrations of CXCL9 from cGVHD patients on no immunosuppressive therapy at the time of sample acquisition (n = 43), cGVHD on any immunosuppressive therapy at the time of sample acquisition (n = 43), and patients with no cGVHD (n = 33). Data are illustrated as box and whisker plots with the whiskers indicating the 90th and 10th percentiles.